title: Assessment of malignancy in pulmonary lesions: FDG dual-head coincidence gamma camera imaging in association with serum tumor marker measurement.
abstract: The purpose of the study was to evaluate the performance of dual-head coincidence gamma camera imaging using FDG in association with serum marker assays in identifying lung carcinoma in patients with abnormal findings on chest radiography.
  
  
  METHODS
  A prospective evaluation of FDG imaging with coincidence detection emission tomography (CDET) using a dual-head gamma camera combined with the assessment of 3 sensitive serum markers of lung cancer (carcinoembryonic antigen, neuron specific enolase, and CYFRA 21-1) was performed on the same day on 58 consecutive patients with known or suspected lung malignancy.
  
  
  RESULTS
  Fifty-three patients were proven to have lung cancer, and 5 patients had benign lung disease. Coincidence imaging showed significantly increased FDG uptake in 49 of 53 patients with proven malignancy (sensitivity, 92.5%) and in 3 patients with benign disease. FDG imaging had negative findings in 4 patients with proven malignancy and 2 patients with benign disease. Serum tumor marker levels were elevated in 42 of 53 cancer patients (sensitivity, 79.2%) and normal in 11 patients with proven malignancy. Nine patients with proven malignancy had positive findings on FDG images and negative marker assays. Two patients with proven malignancy had negative findings on FDG images and positive marker assays. The positive predictive value for lung cancer was 94.2% for FDG alone and 97.6% for FDG in association with serum markers.
  
  
  CONCLUSIONS
  In this study, FDG CDET imaging was a powerful tool for evaluating patients with lung lesions suggestive of malignancy. Although the determination of serum marker levels was less accurate than FDG imaging, positive FDG results found in association with positive markers significantly increased the likelihood of lung malignancy.
authors.affiliation: Department of Nuclear Medicine, CHU, Paris, Bobigny, France.
authors.forename: V
authors.initials: V
authors.lastname: Bousson
authors.forename: J L
authors.initials: JL
authors.lastname: Moretti
authors.forename: P
authors.initials: P
authors.lastname: Weinmann
authors.forename: N
authors.initials: N
authors.lastname: Safi
authors.forename: F
authors.initials: F
authors.lastname: Tamgac
authors.forename: C
authors.initials: C
authors.lastname: Groiselle
authors.forename: V
authors.initials: V
authors.lastname: de Beco
authors.forename: Y
authors.initials: Y
authors.lastname: Hillali
authors.forename: D
authors.initials: D
authors.lastname: Valeyre
authors.forename: J L
authors.initials: JL
authors.lastname: Breau
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D019788:Fluorodeoxyglucose F18; D015902:Gamma Cameras; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008175:Lung Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D010751:Phosphopyruvate Hydratase / Q000097:blood; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D053539:Keratin-19; D019275:Radiopharmaceuticals; C102012:antigen CYFRA21.1; D019788:Fluorodeoxyglucose F18; D007633:Keratins; D010751:Phosphopyruvate Hydratase